Why this matters, without the panic
If you take a GLP-1 medication such as semaglutide, liraglutide, or tirzepatide, you may have noticed a warning about pancreatitis in the leaflet. Questions about GLP-1 pancreatitis tend to be practical: what to do, whom to call, and what to ask before anyone changes your treatment. This post focuses on those steps.
The prescribing information for these drugs includes a warning about acute pancreatitis. Leaflets get updated over time, so check the current text in the FDA's Drugs@FDA database or DailyMed, or in the Anvisa bulário, rather than trusting a copy you saved months ago.
The association comes mainly from spontaneous adverse event reports and observational studies. Those designs can show that two things happen together, but they can't prove that the drug caused the inflammation. That's why the relationship is still debated, and why careful writing says a medication may be associated with pancreatitis. The warning doesn't mean every person who takes these drugs will develop the condition. It also doesn't mean the risk is zero for you. Your prescriber can explain how the available information applies to your history.